Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nanogen and Fisher to Collaborate in Molecular Diagnostics

By HospiMedica staff writers
Posted on 15 Aug 2006
Nanogen (San Diego, CA, USA) and Fisher Scientific (Hampton, NH, USA) have announced that the two companies have expanded their relationship to include a research-and-development collaboration in molecular diagnostics.

Nanogen and Fisher Scientific agreed to share technology and patent rights specifically for the development, manufacture, and marketing of new molecular diagnostic products. More...
Under the agreement, Fisher Scientific may provide up to U.S.$10 million in total during 2007 and 2008 for the research and development of infectious diseases and molecular diagnostic tests that will be mutually agreed upon. The companies believe that the extensive knowledge, intellectual property, and capabilities of both companies will enable molecular diagnostic products to be brought to the market more quickly. Additional details were not disclosed.

Nanogen and Athena Diagnostics, a wholly owned subsidiary of Fisher Scientific International, have agreed to develop, manufacture, and market products based on Athena's proprietary biomarkers for research and for in vitro diagnostic use. Athena has an extensive portfolio of unique markers in the fields of neurology and endocrinology that it has successfully incorporated into its testing service, several of which could be incorporated into assays for use on Nanogen's microarray platform, the NanoChip400. Nanogen also has access to a wide range of markers that could be used to create unique tests for the Athena Diagnostics testing service.

"We see tremendous opportunities in molecular diagnostics and are pleased to be expanding our presence in this rapidly growing market,” said Leland Foster, chief science officer for Fisher Scientific International. "By fostering a collaboration between Nanogen and Athena and furthering Nanogen's R&D efforts, we are advancing the abilities of both companies to bring diagnostic products to the marketplace.”

Nanogen's technologies provide researchers, clinicians, and physicians with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time polymerase chain reaction (PCR) reagents, the NanoChip electronic microarray platform, and a line of rapid diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization and has potential for diagnostic and biodefense applications.

Fisher Scientific facilitates discovery by supplying labs around the world with the tools they need, including biochemicals, cell-culture media, RNAi technology, and rapid diagnostic tests.



Related Links:
Nanogen
Fisher Scientific

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.